[ad_1] Just published: This post hoc analysis compared #suprachoroidal triamcinolone acetonide (CLS-TA) to other commonly available treatments for non-infectious uveitis. #eyes #retina #xipere #uveitis https://t.co/0XXfZFwdPo [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @SEIO_uveitis: Un poco de lectura para esta víspera de reyes, compartimos el siguiente artículo: Suprachoroidal triamcinolone acetonide… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @RetinaToday: Wet AMD, DME, and RVO-ME are leading causes of legal blindness in the industrialized world. Data out to 5 years provide ne…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @ThomasCiullaMD: Just published: Long-Term Outcomes of Anti-VEGF Therapy. Treatment burden is a barrier to real world #outcomes in #AMD… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] Our article earned a top 10 ranking this year… https://t.co/3eBjWfXmEv [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @ThomasCiullaMD: Recently published, “Genes and Gene Therapy in Inherited Retinal Disease”.
#eye #ophthalmology #retina #gene #genether…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Honored to be recognized as a global expert in #maculardegeneration , a leading cause of irreversible vision loss: https://t.co/xLn1Vsjj5a This recognition is based on scientific publications over the last 10 years, an objective process… #AMD #retina #ASRS #clinicalresearch https://t.co/l9bnt4FRuj [ad_2] Source by Thomas Ciulla, …
[ad_1] Just published: Long-Term Outcomes of Anti-VEGF Therapy. Treatment burden is a barrier to real world #outcomes in #AMD, #diabetic & vein occlusion macular edema. Longer acting and more effective treatments are needed… #eye #retina @RetinaToday https://t.co/GuqOGPpmFM [ad_2] Source by Thomas Ciulla, MD, MBA Return …
[ad_1]
RT @OTEurope: XIPERE, the first therapy utilising the suprachoroidal space, demonstrates rapid efficacy, durable benefit and favourable saf…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @ModernRetina: The first retinal gene therapy, voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics), was approved by the FDA in 20… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.